Results of the AiM, PLan, and act on LIFestYles (AMPLIFY) Weight Loss Intervention Among Survivors of Obesity-Related Cancers: A Randomized Clinical Trial.

BackgroundThe number of cancer survivors is growing rapidly, and >70% are overweight or obese. Given their increased risk for obesity-related conditions (eg, cardiovascular disease, second malignancies), weight-loss interventions are a priority for this population, yet few have access.Patients and methodsWe conducted a 2-arm, single-blinded, randomized controlled trial to test whether a 24-week, fully automated, web-based diet intervention would significantly improve body weight and other health-related outcomes compared with a waitlist control among cancer survivors. The AiM, PLan, and act on LIFestYles (AMPLIFY) diet intervention offered serialized, tailored guidance to achieve a 0.5 kg per week weight loss and improve diet quality. Survivors of 1 of 9 obesity-related cancers with >70% 5-year survival, aged ≥50 years, and with a body mass index of 25 to ResultsIntent-to-treat analyses showed significantly greater weight loss among intervention versus waitlist participants (percent weight change, -4.75%; 95% CI, -6.04% to -3.46%), with higher proportions attaining 3%, 5%, and 10% weight loss benchmarks (PConclusionsThe magnitude of weight loss achieved with AMPLIFY is the highest reported to date for any fully automated intervention and produced significant benefits. Continued optimization and research to integrate the AMPLIFY-Diet intervention into broader use and clinical practice are warranted.